Korro Bio, Inc. ((KRRO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Korro Bio, Inc. is conducting a Phase 1/2a clinical study titled A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE). The study aims to assess the safety, tolerability, and pharmacokinetics of KRRO-110, a novel treatment, in healthy adults and those with AATD, a genetic condition affecting lung and liver function.
Intervention/Treatment: The study tests KRRO-110, an RNA editing oligonucleotide encapsulated in a lipid nanoparticle, administered intravenously. The treatment is designed to address Alpha-1 Antitrypsin Deficiency by potentially correcting the underlying genetic mutation.
Study Design: This interventional study is randomized and sequential, with a double-blind masking approach involving both participants and investigators. The primary purpose is treatment, with participants receiving either KRRO-110 or a placebo.
Study Timeline: The study began on November 4, 2024, with the latest update on July 23, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates or results.
Market Implications: The ongoing study of KRRO-110 could significantly impact Korro Bio’s stock performance, as positive results may enhance investor confidence and position the company as a leader in RNA-based therapies. This development could also influence the competitive landscape, prompting responses from other biotech firms working on similar genetic conditions.
The study is currently recruiting, with further details available on the ClinicalTrials portal.